Literature DB >> 28682148

Pharmacokinetics of an intracerebroventricularly administered antibody in rats.

Yuki Noguchi1, Motohiro Kato1, Kazuhisa Ozeki1, Masaki Ishigai1.   

Abstract

The pharmacokinetics (PK) of an antibody in the brain and the spinal cord is insufficiently understood, which is an obstacle to the discovery of antibody drugs that target diseases in the central nervous system. In this study, we focused on the elimination of IgG from cerebrospinal fluid (CSF) circulating in the brain and the spinal cord in rats, and, to evaluate the influence of CSF bulk flow on the clearance of IgG, also examined the PK of inulin in CSF. To monitor their concentrations in CSF, IgG and inulin were co-administered into the lateral ventricle via a catheter, and CSF was collected from the cisterna magna via another catheter time-sequentially. Blood was also obtained from the same individuals, and the concentrations of IgG and inulin in CSF and plasma were measured. The results revealed that PK parameters of IgG were similar to those of inulin; half-life and clearance of IgG were 47.0 ± 6.49 min and 29.0 ± 15.2 mL/day/kg, and those of inulin were 52.8 ± 25.4 min and 29.0 ± 13.3 mL/day/kg. Moreover, deconvolution analysis indicated that all of the IgG administered in the lateral ventricle was transferred to plasma from CSF within 24 hours. This study demonstrated that IgG in CSF was eliminated by bulk flow and transferred totally to blood circulation.

Entities:  

Keywords:  Antibody; CSF; brain; bulk flow; inulin; pharmacokinetics; sequential sampling

Mesh:

Substances:

Year:  2017        PMID: 28682148      PMCID: PMC5627584          DOI: 10.1080/19420862.2017.1345834

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  16 in total

Review 1.  Ageing choroid plexus-cerebrospinal fluid system.

Authors:  J E Preston
Journal:  Microsc Res Tech       Date:  2001-01-01       Impact factor: 2.769

2.  In vitro and in vivo methods for assessing FcRn-mediated reverse transcytosis across the blood-brain barrier.

Authors:  Nadia Caram-Salas; Eve Boileau; Graham K Farrington; Ellen Garber; Eric Brunette; Abedelnasser Abulrob; Danica Stanimirovic
Journal:  Methods Mol Biol       Date:  2011

Review 3.  Targeted delivery of protein and gene medicines through the blood-brain barrier.

Authors:  W M Pardridge
Journal:  Clin Pharmacol Ther       Date:  2014-12-15       Impact factor: 6.875

4.  Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse.

Authors:  H J Lee; B Engelhardt; J Lesley; U Bickel; W M Pardridge
Journal:  J Pharmacol Exp Ther       Date:  2000-03       Impact factor: 4.030

5.  Pharmacokinetics of IgG and IgM anti-ganglioside antibodies in rats and monkeys after intrathecal administration.

Authors:  I Bergman; G J Burckart; C R Pohl; R Venkataramanan; M A Barmada; J A Griffin; N K Cheung
Journal:  J Pharmacol Exp Ther       Date:  1998-01       Impact factor: 4.030

6.  Amyloid-β peptide(1-40) elimination from cerebrospinal fluid involves low-density lipoprotein receptor-related protein 1 at the blood-cerebrospinal fluid barrier.

Authors:  Masachika Fujiyoshi; Masanori Tachikawa; Sumio Ohtsuki; Shingo Ito; Yasuo Uchida; Shin-Ichi Akanuma; Junichi Kamiie; Tadafumi Hashimoto; Ken-Ichi Hosoya; Takeshi Iwatsubo; Tetsuya Terasaki
Journal:  J Neurochem       Date:  2011-06-17       Impact factor: 5.372

7.  Formycin B elimination from the cerebrospinal fluid of the rat.

Authors:  X Wu; A C Hui; K M Giacomini
Journal:  Pharm Res       Date:  1993-04       Impact factor: 4.200

8.  Effect of hypertension on the integrity of blood brain and blood CSF barriers, cerebral blood flow and CSF secretion in the rat.

Authors:  Hameed Al-Sarraf; Laila Philip
Journal:  Brain Res       Date:  2003-06-13       Impact factor: 3.252

9.  Efflux of monoclonal antibodies from rat brain by neonatal Fc receptor, FcRn.

Authors:  Philip R Cooper; Gary J Ciambrone; Connie M Kliwinski; Eva Maze; Lowell Johnson; Qianqiu Li; Yiqing Feng; Pamela J Hornby
Journal:  Brain Res       Date:  2013-08-23       Impact factor: 3.252

10.  Drug transport in brain via the cerebrospinal fluid.

Authors:  William M Pardridge
Journal:  Fluids Barriers CNS       Date:  2011-01-18
View more
  6 in total

1.  CXCL13/CXCR5 signalling is pivotal to preserve motor neurons in amyotrophic lateral sclerosis.

Authors:  Maria Chiara Trolese; Alessandro Mariani; Mineko Terao; Massimiliano de Paola; Paola Fabbrizio; Francesca Sironi; Mami Kurosaki; Silvia Bonanno; Silvia Marcuzzo; Pia Bernasconi; Francesca Trojsi; Eleonora Aronica; Caterina Bendotti; Giovanni Nardo
Journal:  EBioMedicine       Date:  2020-11-09       Impact factor: 8.143

2.  A translational platform PBPK model for antibody disposition in the brain.

Authors:  Hsueh-Yuan Chang; Shengjia Wu; Guy Meno-Tetang; Dhaval K Shah
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-05-21       Impact factor: 2.745

3.  Standard treatment-refractory cytomegalovirus encephalitis unmasked by immune reconstitution inflammatory syndrome and successfully treated with virus-specific hyperimmune globulin.

Authors:  Natalia Maximova; Annalisa Marcuzzi; Irene Del Rizzo; Davide Zanon; Alessandra Maestro; Egidio Barbi; Roberto Sala
Journal:  Clin Transl Immunology       Date:  2020-11-17

4.  Investigating surrogate cerebrospinal fluid matrix compositions for use in quantitative LC-MS analysis of therapeutic antibodies in the cerebrospinal fluid.

Authors:  Jens Rose Fogh; Anne-Marie Jacobsen; Tam T T N Nguyen; Kasper D Rand; Line Rørbæk Olsen
Journal:  Anal Bioanal Chem       Date:  2020-02-01       Impact factor: 4.142

5.  The atlas of RNase H antisense oligonucleotide distribution and activity in the CNS of rodents and non-human primates following central administration.

Authors:  Paymaan Jafar-Nejad; Berit Powers; Armand Soriano; Hien Zhao; Daniel A Norris; John Matson; Beatrice DeBrosse-Serra; Jamie Watson; Padmakumar Narayanan; Seung J Chun; Curt Mazur; Holly Kordasiewicz; Eric E Swayze; Frank Rigo
Journal:  Nucleic Acids Res       Date:  2021-01-25       Impact factor: 16.971

6.  Autoantibodies against NCAM1 from patients with schizophrenia cause schizophrenia-related behavior and changes in synapses in mice.

Authors:  Hiroki Shiwaku; Shingo Katayama; Kanoh Kondo; Yuri Nakano; Hikari Tanaka; Yuki Yoshioka; Kyota Fujita; Haruna Tamaki; Hironao Takebayashi; Omi Terasaki; Yukihiro Nagase; Teruyoshi Nagase; Tetsuo Kubota; Kinya Ishikawa; Hitoshi Okazawa; Hidehiko Takahashi
Journal:  Cell Rep Med       Date:  2022-04-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.